Klaria Pharma
Klaria Interim Report Q3 2023
Summary of the Interim Report
Net sales of 0.6 MSEK (0.0 MSEK)
Other income amounted to 0.0 MSEK (0.0 MSEK)
Third quarter of 2023
- R&D costs for the period amounted to 7.4 MSEK (10.9 MSEK)
- Profit after tax amounted to -10.8 MSEK (16.1 MSEK) ∞ Earnings per share for the quarter amounted to -0.10 SEK (-0.27 SEK)
- Cash flow from operating activities amounted to -7.3 MSEK (-3.6 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 2.3 MSEK (6.7 MSEK)
- Cash and cash equivalents on the balance sheet date amounted to 50.7 MSEK (39.3 MSEK)
The period January–September 2023
- Net sales of 7.1 MSEK (3.7 MSEK)
- Other income amounted to 0.3 MSEK (0.4 MSEK)
- R&D costs for the period amounted to 23.0 MSEK (42.7 MSEK)
- Profit after tax amounted to -26.3 MSEK (-50.9 MSEK)
- Earnings per share for the quarter amounted to -0.27 SEK (-0.88 SEK)
- Cash flow from operating activities amounted to -18.6 MSEK (-39.1 MSEK)
| Datum | 2023-11-24, kl 14:30 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.